NCT04074187 - A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2019

Primary Completion Date

May 19, 2021

Study Completion Date

May 19, 2021

Conditions

Thrombotic Thrombocytopenic Purpura

Interventions

DRUG

Caplacizumab (ALX-0081)

Pharmaceutical form:Lyophilized powder for solution for injection Route of administration: IV (first dose), SC (all subsequent doses)

DRUG

Plasma exchange (PE)

Pharmaceutical form:Plasma (e.g. fresh frozen plasma) Route of administration: Plasma exchange

DRUG

Corticosteroid treatment (Methylprednisolone or prednisolone)

Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral

DRUG

Immunosuppressive treatment (eg, rituximab)

Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)

Trial Locations (12)

Investigational Site Number 3920009, Iruma-Gun

Investigational Site Number 3920014, Kanazawa

Investigational Site Number 3920007, Kashihara-shi

Investigational Site Number 3920013, Kawasaki-Shi

Investigational Site Number 3920001, Kitakyushu-Shi

Investigational Site Number 3920002, Kumamoto

Investigational Site Number 3920003, Kurashiki-Shi

Investigational Site Number 3920010, Kyoto

Investigational Site Number 3920005, Maebashi

Investigational Site Number 3920015, Nagoya

Investigational Site Number 3920011, Osaka

Investigational Site Number 3920006, Sendai